FDA - why are they so NEGATIVE when it comes to the approval of the RESAPP concept.
Are they blind, stupid or deliberately not aware of its potential as a WARNING DEVICE to lung failure in COVID-19 infected patients?
The following abstract from NYTimes ....4th April 2020

A German Exception? Why the Country’s Coronavirus Death Rate Is Low
The pandemic has hit Germany hard, with more than 92,000 people infected. But the percentage of fatal cases has been remarkably low compared to those in many neighboring countries.

They call them corona taxis: Medics outfitted in protective gear, driving around the empty streets of Heidelberg to check on patients who are at home, five or six days into being sick with the coronavirus.

They take a blood test, looking for signs that a patient is about to go into a steep decline. They might suggest hospitalization, even to a patient who has only mild symptoms; the chances of surviving that decline are vastly improved by being in a hospital when it begins.

“There is this tipping point at the end of the first week,” said Prof. Hans-Georg Kräusslich, the head of virology at University Hospital in Heidelberg, one of Germany’s leading research hospitals.

If you are a person whose lungs might fail, that’s when you will start deteriorating

but with 1,295 deaths, Germany’s fatality rate stood at 1.4 percent, compared with 12 percent in Italy, around 10 percent in Spain, France and Britain, 4 percent in China and 2.5 percent in the United States. Even South Korea, a model of flattening the curve, has a higher fatality rate, 1.7 percent.

But there are also significant medical factors that have kept the number of deaths in Germany relatively low, epidemiologists and virologists say, chief among them early and widespread testing and treatment, plenty of intensive care beds and a trusted government whose social distancing guidelines are widely observed

By now someone out there in FDA should have recognized that any TELEHEALTH device application (ie RESAPP) that could be used to study unhealthy lung performance in SUSPECTED COVID-19 patients could be used to at least give DETERIORATING INITIAL warnings signs that this patient needs IMMEDIATE help, if they were being testing in an outside environment.